Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IAPP | P10997 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16842402 | 0.93 | HSD17B10 (0.35) | KDM4EMAPTHSD17B10POLBALDH1A1 | |
| SCHEMBL4232771 | 0.87 | TDP1 (0.32) | KDM4EMAPTPOLBALDH1A1 | |
| SCHEMBL267389 | 0.79 | ALDH1A1 (0.35) | KDM4EMAPTPOLBALDH1A1 | |
| SCHEMBL11475333 | 0.79 | TDP1 (0.35) | KDM4EMAPTPOLBALDH1A1IAPP | |
| SCHEMBL11950895 | 0.78 | TSHR (0.32) | KDM4EMAPTPOLBALDH1A1 | |
| SCHEMBL11152788 | 0.78 | MEN1 (0.34) | KDM4EMAPTPOLBMEN1ALDH1A1 | |
| SCHEMBL14261181 | 0.74 | ALDH1A1 (0.35) | KDM4EMAPTPOLBALDH1A1 | |
| SCHEMBL6742601 | 0.73 | SIRT2 (0.39) | HSD17B10 | |
| SCHEMBL6535095 | 0.73 | PTPN1 (0.33) | KDM4EMAPTPOLBALDH1A1 | |
| SCHEMBL2541730 | 0.71 | ALDH1A1 (0.38) | KDM4EMAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814338-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814338-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11192852-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200207706-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-9884809-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884809-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-2651902-B1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160130220-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130220-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-9174941-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174941-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140051739-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140051739-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. | 2014-02-20 | — | — | US | disclosed |
| US-8513436-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513436-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | REATA PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120196880-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. | 2012-08-02 | — | — | US | disclosed |
| US-20120196880-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. | 2012-08-02 | — | — | US | disclosed |
| WO-2012083306-A2 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207706-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | GPX4, MPO, GPX1 | KDM4E 3639/4885MAPT 3304/4885HSD17B10 1387/4885 |
| US-20160130220-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | GPX4, MPO, GPX1 | KDM4E 3639/4885MAPT 3304/4885HSD17B10 1387/4885 |
| US-11192852-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | GPX4, MPO, GPX1 | KDM4E 3639/4885MAPT 3304/4885HSD17B10 1387/4885 |
| US-20140051739-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | GPX4, MPO, GPX1 | KDM4E 3639/4885MAPT 3304/4885HSD17B10 1387/4885 |
| US-11814338-B2 | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | GPX4, MPO, GPX1 | KDM4E 3639/4885MAPT 3304/4885HSD17B10 1387/4885 |
| US-20120196880-A1 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | GPX4, MPO, GPX1 | KDM4E 3639/4885MAPT 3304/4885HSD17B10 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.